Evidence map›Paper›PMID 31315887›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2019

Efficient CD4Cre-Mediated Conditional KRas Expression in Alveolar Macrophages and Alveolar Epithelial Cells Causes Fatal Hyperproliferative Pneumonitis.

Pengcheng Chen, Shang Wang, Kyathanahalli S Janardhan, Rachel L Zemans, Wenhai Deng, Peer Karmaus, Shudan Shen, Mary Sunday, Loretta G Que, Michael B Fessler and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Pengcheng ChenDepartment of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC 27710.
Shang WangDepartment of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC 27710.
Kyathanahalli S JanardhanIntegrated Laboratory Systems, Inc., and National Institutes of Health, Research Triangle Park, Durham, NC 27709.ORCID 0000-0002-5774-9317
Rachel L ZemansDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109.ORCID 0000-0003-3537-9869
Wenhai DengDepartment of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC 27710.ORCID 0000-0003-3270-5980
Peer KarmausImmunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, Durham, NC 27709.
Shudan ShenDepartment of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC 27710.
Mary SundayDepartment of Pathology, Duke University Medical Center, Durham, NC 27710.
Loretta G QueDepartment of Medicine, Duke University Medical Center, Durham, NC 27710.ORCID 0000-0001-9188-9244
Michael B FesslerImmunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, Durham, NC 27709.
Xiao-Ping ZhongDepartment of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC 27710; xiaoping.zhong@duke.edu.ORCID 0000-0002-4619-8783
Duke Medical Center · USNational Institutes of Health · USUniversity of Michigan · US

Funding

Cell Signaling of Host DefenseZIAES102005 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI FESSLER, MICHAEL B · 2009 to 2025
$41.7M
Regulation of peripheral T cell toleranceR01AI079088 · NIAID · DUKE UNIVERSITY · PI ZHONG, XIAOPING · 2008 to 2019
$3.5M
Cell Signaling of Host DefenseZ01ES102005 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI FESSLER, MICHAEL B · 2006 to 2008
$3.3M
TSC1-mTOR signaling and T cell toleranceR01AI101206 · NIAID · DUKE UNIVERSITY · PI ZHONG, XIAOPING · 2012 to 2016
$1.9M
Intramural NIH HHS Z01 ES102005NIAID NIH HHS R01 AI079088NIAID NIH HHS R01 AI101206
6 · The paper itself

Abstract

The CD4Cre transgenic model has been widely used for T cell-specific gene manipulation. We report unexpected highly efficient Cre-mediated recombination in alveolar macrophages (AMFs), bronchial epithelial cells (BECs), and alveolar epithelial cells (AECs) in this strain of mice. Different from CD4 T cells, AMFs, AECs, and BECs do not express detectable Cre protein, suggesting that Cre protein is either very transiently expressed in these cells or only expressed in their precursors. Mice carrying a conditional constitutively active KRas (caKRas) allele and the CD4Cre transgene contain not only hyperactivated T cells but also develop severe AMF accumulation, AEC and BEC hyperplasia, and adenomas in the lung, leading to early lethality correlated with caKRas expression in these cells. We propose that caKRas-CD4Cre mice represent, to our knowledge, a novel model of proliferative pneumonitis involving macrophages and epithelial cells and that the CD4Cre model may offer unique usefulness for studying gene functions simultaneously in multilineages in the lung. Our observations, additionally, suggest that caution in data interpretation is warranted when using the CD4Cre transgenic model for T cell-specific gene manipulation, particularly when lung pathophysiological status is being examined.

Indexed as

Alveolar Epithelial CellsAnimalsCD4 AntigensHyperplasiaIntegrasesMacrophages, AlveolarMiceMice, Inbred C57BLPneumoniaProto-Oncogene Proteins p21(ras)Recombination, GeneticTransgenesCD4 AntigensCre recombinaseHras protein, mouseIntegrasesProto-Oncogene Proteins p21(ras)

Identifiers

PMID31315887
PMCPMC6702086
OpenAlexW2958596585

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.